AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20817013
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg HA antigen dose
Trial: 20817013
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of 30 μg HA antigen
Trial: 20817013
Drug: Vaccine overall
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine overall
Trial: 18399337
Drug: Misoprostol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (50 microg intravaginally every 6 hours, maximum of 4 doses)
Trial: 10457872
Drug: Tamoxifen 40
RxNorm normalized name: tamoxifen 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 40 mg followed by 800 micrograms of misoprostol (phase 1)
Trial: 10457872
Drug: Methotrexate 50
RxNorm normalized name: methotrexate 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 50 mg/m2 followed by 800 micrograms of misoprostol (phase 1)
Trial: 10457872
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg twice daily for 4 days followed by 800 micrograms of misoprostol (phase 2)
Trial: 2467711
Drug: Iloprost intravenous
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost intravenous infusions starting at 0.5 ng/kg/min and increased by 0.5 ng/kg/min every 15 minutes to a maximum of 2.0 ng/kg/min for eight hours on three consecutive days with a further single infusion at week 8.
Trial: 2467711
Drug: Nifedipine starting
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine starting at 30 mg daily and increased to 60 mg daily after four weeks for another 12 weeks.
Trial: 135163
Drug: Dimenhydrinate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate (2 mg/kg)
Trial: 135163
Drug: Sulpirid (2.86
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpirid (2.86 mg/kg)
Trial: 25197025
Drug: ISIS 325568
RxNorm normalized name: ISIS 325568
DrugBank: ISIS 325568 (DB06099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 325568 (400 mg/week)
Trial: 23635996
Drug: MgSO4 30
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MgSO4 30 mg kg(‐1) intravenously for 10 min, then continuous infusion at 1 g h(‐1)
Trial: 21957896
Drug: Quinapril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril treatment for 3 months
Trial: 19123333
Drug: Combined massage-smouldering-washing
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined massage-smouldering-washing therapy (MSW)
Trial: 19123333
Drug: Mini-invasive surgery
RxNorm normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-invasive surgery by arthroscopic mopping with sodium hyaluronate injection
Trial: 16297965
Drug: Patch tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch tests for sensitivity to cadmium
Trial: 7693029
Drug: 5 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 micrograms/kg rG‐CSF after induction therapy
Trial: 7693029
Drug: 10 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms/kg rG‐CSF after induction therapy
Trial: 7693029
Drug: 2 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 micrograms/kg rG‐CSF after consolidation therapy
Trial: 7693029
Drug: 5 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 micrograms/kg rG‐CSF after consolidation therapy
Trial: 7693029
Drug: 10 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms/kg rG‐CSF after consolidation therapy
Trial: 7693029
Drug: No rG‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rG‐CSF after consolidation therapy
Trial: 27144545
Drug: Wild-type KRAS
RxNorm normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wild-type KRAS patients treated with anti-EGFR agent
Trial: 18795588
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg (for patients initially on RSV 10 mg who were uncontrolled)
Trial: 18795588
Drug: Switch from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from Atorvastatin 10 mg to Rosuvastatin 10 mg (for patients initially on ATV 10 mg who were uncontrolled)
Trial: 8599316
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g supplemental Ca/d as calcium carbonate (in lactating and nonlactating women)
Trial: 30485409
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of relaxation and physical activity
Trial: 27193480
Drug: Two implant-supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two implant-supported overdentures
Trial: 27193480
Drug: Four implant-supported
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four implant-supported overdentures
Trial: 20653227
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of background visual motion and relative movement of sound while sitting at a desk
Trial: 8417512
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Hydralazine + Nitroglycerin)
Trial: 2941277
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 100 mg
Trial: 2941277
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 750 mg
Trial: 2941277
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 250 mg (after breakfast)
Trial: 2941277
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin 200 mg (20 min infusion)
Trial: 2941277
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (various doses)
Trial: 2941277
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin (various doses)
Trial: 2941277
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 250 mg
Trial: 29901903
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose MgSO4 (10 gm)
Trial: 29901903
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose MgSO4 (5 gm)
Trial: 20145260
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) moxifloxacin
Trial: 31003911
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus cobimetinib (840 mg intravenously every 2 weeks + 60 mg orally once daily for days 1–21 of a 28-day cycle)
Trial: 31003911
Drug: Atezolizumab monotherapy
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab monotherapy (1200 mg intravenously every 3 weeks)
Trial: 31003911
Drug: Regorafenib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (160 mg orally once daily for days 1–21 of a 28-day cycle)
Trial: 23859672
Drug: 2 g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of cefazolin
Trial: 23859672
Drug: 4 g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of cefazolin
Trial: 15088127
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous interleukin 2 (IL-2) and interferon alpha (IFN-alpha) alone (n = 23)
Trial: 15088127
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous interleukin 2 (IL-2) and interferon alpha (IFN-alpha) in combination with histamine dihydrochloride (n = 26)
Trial: 15088127
Drug: Cytokine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine therapy (IL-2 and IFN-alpha)
Trial: 11418230
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment (for those with high PRL response)
Trial: 11418230
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment (for those with low PRL response)
Trial: 9876958
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg xanomeline tartrate three times daily (t.i.d.)
Trial: 7976162
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium bromide 0.6 mg kg‐1 during balanced anesthesia (nitrous oxide and fentanyl)
Trial: 7976162
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium bromide 0.6 mg kg‐1 during halothane anesthesia
Trial: 7976162
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium bromide 0.9 mg kg‐1 during balanced anesthesia (nitrous oxide and fentanyl)
Trial: 7976162
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium bromide 0.9 mg kg‐1 during halothane anesthesia
Trial: 7976162
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium bromide 0.9 mg kg‐1 during anesthesia with nitrous oxide, oxygen, and isoflurane
Trial: 2514694
Drug: Glycolande N
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycolande N (modified glibenclamide formulation)
Trial: 2514694
Drug: Marketed standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed standard preparation (glibenclamide)
Trial: 1104076
Drug: Tetrabid-Organon (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrabid-Organon (sustained-release tetracycline hydrochloride)
Trial: 27876790
Drug: MR-antagonist spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MR-antagonist spironolactone
Trial: 18714620
Drug: Traditional continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional continuous intravenous infusion
Trial: 16441475
Drug: Polyethylene glycol-electrolyte
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol-electrolyte solution (PEG-ELS)
Trial: 12940870
Drug: Isoflavones from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones from red clover (approximately 50 mg/day for 4 weeks)
Trial: 10741114
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of Iopamiron 300 mgI/ml (group 1)
Trial: 10741114
Drug: 2 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml/kg of Iopamiron 300 mgI/ml (group 2)
Trial: 1396619
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg daily
Trial: 1396619
Drug: Timolol 10
RxNorm normalized name: timolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 10 mg daily
Trial: 2865710
Drug: Levobunolol (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobunolol (0.5% and 1%) twice daily
Trial: 29747594
Drug: Clinic referral
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic referral / ongoing treatment (Treated Group)
Trial: 29747594
Drug: No Treatment
RxNorm normalized name: NO
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No Treatment (No Treatment Group)
Trial: 16235460
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of hyperbaric bupivacaine combined with 2 mg of midazolam intrathecally (M+M)
Trial: 16235460
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of hyperbaric bupivacaine (M)
Trial: 10973391
Drug: Optimal values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal values (cardiac index >4.5 L/min/m2, ratio of transcutaneous oxygen tension to fractional inspired oxygen >200, oxygen delivery index >600 mL/min/m2, and oxygen consumption index >170 mL/min/m2)
Trial: 8993081
Drug: Fluoxetine; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine; specific dosage and duration not mentioned
Trial: 8993081
Drug: Placebo; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; specific dosage and duration not mentioned
Trial: 1620908
Drug: Sham pulsations
RxNorm normalized name: ABG Pulsator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham pulsations (placebo treatment)
Trial: 27892594
Drug: Chloroprocaine 10
RxNorm normalized name: chloroprocaine 10 mg/mL intrathecal solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroprocaine 10 mg/ml (10 mg)
Trial: 27892594
Drug: Chloroprocaine 10
RxNorm normalized name: chloroprocaine 10 mg/mL intrathecal solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroprocaine 10 mg/ml (20 mg)
Trial: 27892594
Drug: Chloroprocaine 10
RxNorm normalized name: chloroprocaine 10 mg/mL intrathecal solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroprocaine 10 mg/ml (30 mg)
Trial: 26614144
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg kg(‐1) induction, 6‐10 mg kg(‐1)h(‐1) maintenance
Trial: 26614144
Drug: Midazolam 0.5
RxNorm normalized name: midazolam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.5 mg kg(‐1) induction, 0.5 mg kg(‐1) maintenance
Trial: 22185846
Drug: Hibiscus sabadariffa
RxNorm normalized name: Hibiscus sabdariffa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hibiscus sabadariffa extract (SHE) standardized 10 mg of anthocyanins
Trial: 22185846
Drug: Hibiscus sabadariffa
RxNorm normalized name: Hibiscus sabdariffa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hibiscus sabadariffa extract (SHE) standardized 20 mg of anthocyanins for 12 weeks
Trial: 11510804
Drug: Keliximab 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keliximab 0.5 mg/kg
Trial: 11510804
Drug: Keliximab 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keliximab 1.5 mg/kg
Trial: 11510804
Drug: Keliximab 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keliximab 3.0 mg/kg
Trial: 11510804
Drug: Keliximab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keliximab (all doses combined)
Trial: 9764780
Drug: pVL nadir
RxNorm normalized name: NAIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pVL nadir < or = 20 copies/ml
Trial: 9764780
Drug: pVL nadir
RxNorm normalized name: NAIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pVL nadir between 20 and 400 copies/ml
Trial: 9764780
Drug: pVL nadir
RxNorm normalized name: NAIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pVL nadir > 400 copies/ml
Trial: 3296353
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) treatment for 90 days followed by conversion to azathioprine and prednisolone
Trial: 3296353
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (AP) with azathioprine and prednisolone throughout
Trial: 17935920
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 1 ml methylprednisolone (40 mg/ml), 0.5 ml Lidocaine (5mg/ml), and 0.15 ml gadolinium (Omniscan 0.5 mmol/ml) into the wrist joint.
Trial: 12765810
Drug: Mild hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hypothermia (rectal temperature 32.0 to 35.0 degrees C)
Trial: 12765810
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rectal temperature 36.5 to 37.0 degrees C)
Trial: 10834773
Drug: Procaine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine (100 mg hyperbaric)
Trial: 10834773
Drug: Lidocaine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (50 mg hyperbaric)
Trial: 27824753
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 550 mg given 1 hour before IUD insertion
Trial: 22313793
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (3 g/d) and kinako (29 g/d)
Trial: 22313793
Drug: Kinako (29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinako (29 g/d)
Trial: 24290606
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (3 g/d)
Trial: 10696629
Drug: omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 fatty acids (5.4 g/d)
Trial: 10696629
Drug: sulfasalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfasalazine (2 g/d)
Trial: 9356106
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline injection (10 mL) at L2‐3 or L3‐4 interspace 10 min after spinal anesthesia
Trial: 9356106
Drug: No epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No epidural saline injection (Control group)
Trial: 2871010
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate 5 mg every 2 weeks
Trial: 2871010
Drug: Fluphenazine 5
RxNorm normalized name: fluphenazine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine 5 mg daily
Trial: 2871010
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of antipsychotic drugs
Trial: 31847348
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) - intermittent use formulation (gum, sprays, inhaler)
Trial: 24891337
Drug: FeNO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeNO treatment strategy
Trial: 20391859
Drug: Direct person‐to‐person
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct person‐to‐person prayer intervention (six weekly 1-hour sessions)
Trial: 16968235
Drug: Average log
RxNorm normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average log DNA copy number/ml during clinical stage
Trial: 16968235
Drug: Average log
RxNorm normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average log DNA copy number/ml during subclinical stage
Trial: 8801151
Drug: Prostaglandin F2
RxNorm normalized name: Prostaglandin F2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2 alpha (20 mg in 20 ml normal saline)
Trial: 8801151
Drug: Oxytocin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (30 IU in 20 ml normal saline)
Trial: 8801151
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (20 ml)
Trial: 1325772
Drug: alpha h‐ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha h‐ANP (99‐126), 25 micrograms intravenously followed by infusion of 0.1 microgram kg‐1 min‐1
Trial: 30497132
Drug: Depomedrol (DEPO)
RxNorm normalized name: epomediol
DrugBank: Epomediol (DB13802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depomedrol (DEPO) - 1 ml (80 mg) applied directly to the surgical site
Trial: 30497132
Drug: No Depomedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Depomedrol (NODEPO) - 1 ml saline on Gelfoam carrier
Trial: 24758565
Drug: DIMS0150 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIMS0150 (30 mg rectal administration)
Trial: 17875241
Drug: Alprostadil 5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprostadil 5‐20 microg powder for injection